Developing Abuse-Deterrent
Medications to Reduce
the Potential for Harm
Vallon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders.
Our Technology is Designed to Resist Manipulation for Snorting and Provide Barriers to Injection
Our lead investigational product candidate, ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), is a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine designed to deter attempts to crush and snort and provides barriers to injection.
Prescription Stimulant Abuse is a Large and Growing Concern
5+ million
adolescents and adults misuse prescription stimulants annually1
From 2004 – 2011, emergency department visits due to non-medical use of stimulants2
Increased 4.7x
From 2010 – 2017, deaths associated with prescription stimulants3
Increased 5x
Sources: 1. SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2018; 2. Drug Abuse Warning Network, 2011; 3. Black, CPDD, 2020.
